Kristine Van Natta (Presenter)
Thermo Fisher Scientific
Authorship: Kristine Van Natta, Pengxiang Yang, Marta Kozak
Thermo Fisher Scientific, San Jose, CA
| Short Abstract To evaluate performance of a new four-channel LC systems we developed short, efficient methods optimized for different classes of compounds including antipsychotics, antibiotics, anticonvulsants, immunosuppressants, antiarrhythmics, and antidepressants in plasma, serum or blood. The methods were implemented on a new 4-channel LC interfaced to a triple quadrupole mass spectrometer. Each LC channel ran a method optimized for a specific group of compounds. This enabled fast, open access style analysis of any group without having to change or re-equilibrate LC columns or mobile phases. The system performance evaluation was assessed by obtaining overall system productivity and also LOQ, precision and matrix effects for individual methods. Stability of the calibration curve over time was also investigated to evaluate open access functionality. |
Long Abstract
To evaluate performance of a new four-channel LC systems we developed short, efficient methods optimized for different classes of compounds including antipsychotics, antibiotics, anticonvulsants, immunosuppressants, antiarrhythmics, and antidepressants in plasma, serum or blood. The methods were implemented on a new 4-channel LC interfaced to a triple quadrupole mass spectrometer. Each LC channel ran a method optimized for a specific group of compounds. This enabled fast, open access style analysis of any group without having to change or re-equilibrate LC columns or mobile phases. The system performance evaluation was assessed by obtaining overall system productivity and also LOQ, precision and matrix effects for individual methods. Stability of the calibration curve over time was also investigated to evaluate open access functionality. These analytical methods are to demonstrate analytical capabilities of instruments and workflow, and have not been validated and are not intended to be used for reporting anything else other than analytical performance.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | yes | Thermo Fisher Scientific |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | yes |